By June Kinoshita, Director of Research and Patient Engagement “Positive benefit/risk supports losmapimod’s potential to be a transformative therapy for the treatment of FSHD”—Fulcrum Therapeutics Fulcrum Therapeutics announced today that… Read More »
ReDUX4 trial result exceeds expectations
Hot off the press – FSHD Advocate
Our new issue of the FSHD Advocate, the first of 2021, is now available online. For those of you who receive our flagship magazine by the postal service, it will… Read More »
FSHD Society releases Voice of the Patient Report
Landmark report captures compelling testimony by patients and family members about the severity of disease symptoms and urgent need for treatment LEXINGTON, MASS. (PRWEB) NOVEMBER 12, 2020 The FSHD Society has… Read More »
Glee star is Walk & Roll national ambassador
The FSHD Society announced today that Max Adler, an actor best known for his roles on the hit series “Glee,” available for streaming on Netflix, and “Switched at Birth”, is… Read More »
FSHD Clinical Trial Research Network expands to four new sites
The FSHD Society announced today that it has awarded $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on funding of $300,000 a… Read More »